LifeSemantics Ventures into 'Business Diversification' by Acquiring Alteogen Subsidiary's Business

Digital healthcare specialist LifeSemantics is expanding its business scope into the pharmaceutical and bio industries through the acquisition of the antibiotic and immunosuppressant business of Alteogen's subsidiary.

Life Semantics Office Building Exterior [Photo by Life Semantics]

NutraSemantics, a subsidiary of LifeSemantics, announced on the 22nd that it will acquire the business division of Ceres FND, a subsidiary of the biopharmaceutical platform company Alteogen. NutraSemantics held an extraordinary board meeting the day before and approved the agenda. The acquisition target is the comprehensive business of manufacturing, sales, and marketing of antibiotics and immunosuppressants of Ceres FND. NutraSemantics plans to take over everything from the production plant, land, machinery, technology, patents, and research institute, as well as the employees.

Ceres FND is equipped with facilities certified for Good Manufacturing Practice (GMP) and produces antibiotics such as vancomycin and teicoplanin, prescribed to patients infected with superbugs, as well as the immunosuppressant tacrolimus. It is also preparing to produce the anticancer drug everolimus, used for treating breast and kidney cancers. The combined global market size of vancomycin, teicoplanin, tacrolimus, and everolimus reached a total of $23.7 billion (approximately 31 trillion KRW) as of last year. Furthermore, mass production and full-scale supply of immunosuppressants, topical ointments, and anticancer drugs are expected to begin early next year.

NutraSemantics plans to expand its business area through the production of antibiotic raw materials and immunosuppressants using biological techniques and research and development of anticancer drugs. Additionally, it aims to secure core raw material production capabilities for high-quality health functional foods, including strain development, fermentation, and high-purity purification, and diversify its business portfolio with anticancer drug development to accelerate performance improvement next year.

LifeSemantics is establishing subsidiaries NutraSemantics, a health functional food company, and NexusBridge, a data-based finance and healthcare product sales company, to secure mid- to long-term growth engines and solidify its position as a healthcare company covering the entire health management cycle. Through this business acquisition, it is expected to directly contribute to the healing journey and leverage the expanded base in the pharmaceutical and bio industries to create synergy, thereby strengthening the competitiveness of its existing digital healthcare business.

Lee Byung-joo, CEO of NutraSemantics, said, “This business acquisition is expected to be a driving force to expand the growth momentum not only for NutraSemantics but also for its parent company LifeSemantics.” He added, “By expanding the bio and pharmaceutical business sectors in addition to the existing health functional food business through the production know-how and facility infrastructure possessed by Ceres FND, we will produce high-quality core raw materials and manufacture customized health functional foods tailored to customers’ health conditions, securing competitiveness in the global market beyond Korea.”

This content was produced with the assistance of AI translation services.